articleJournal of Clinical OncologyApr 5, 2011BRONZE OA

Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation

Cleveland Clinic · UF Health Shands Hospital · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Results

Median follow-up was 9 years, and 3,788 patients had been observed for 10 or more years. The probability of being alive 10 years after HCT was 85%. The chief risk factors for late death included older age and chronic graft-versus-host disease (GVHD). For patients who underwent transplantation for malignancy, relapse was the most common cause of death. The greatest risk factor for late relapse was advanced disease at transplantation. Principal risk factors for nonrelapse deaths were older age and GVHD. When compared with age, sex, and nationality-matched general population, late deaths remained higher than expected for each disease, with the possible exception of lymphoma, although the relative risk generally receded over time.

Conclusion

The prospect for long-term survival is excellent for 2-year survivors of allogeneic HCT. However, life expectancy remains lower than expected. Performance of HCT earlier in the course of disease, control of GVHD, enhancement of immune reconstitution, less toxic regimens, and prevention and early treatment of late complications are needed.

Citation impact

627
total citations
FWCI
12.43
Percentile
100%
References
34
Citations per year

Authors

11

Topics & keywords

Keywords
  • Medicine
  • Transplantation
  • Population
  • Cause of death
  • Disease
  • Internal medicine
  • Cohort
  • Surgery
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding